REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|January 31, 2022
Pharmacy Clinical Pearl of the Day: Grand Mal Seizures
Author(s)Saro Arakelians, PharmD
Many people who experience a grand mal seizure never have another one and don't need treatment.
Advertisement
Clinical Pearl of the Day: Grand Mal Seizures
A grand mal seizure causes a loss of consciousness and violent muscle contractions.
Insight:
- Grand mal seizures are the type most commonly associated with seizures.
- A grand mal seizure—also known as a generalized tonic-clonic seizure—is caused by abnormal electrical activity throughout the brain.
- Usually, a grand mal seizure is caused by epilepsy. However, sometimes this type of seizure can be triggered by other health problems, such as extremely low blood sugar, a high fever, or a stroke.
- Many people who experience a grand mal seizure never have another one and don't need treatment. But someone who has recurrent seizures may need treatment with daily anti-seizure medications to control and prevent future grand mal seizures.
- Symptoms include loss of consciousness, contractions, and falling.
- Diagnosis includes neurological exam, blood test, lumbar puncture, CT, MRI, or PET exam.
- Treatment includes medications such as carbamazepine (Carbatrol, Tegretol), phenytoin (Dilantin, Phenytek), valproic acid (Depakene), oxcarbazepine (Oxtellar, Trileptal), lamotrigine (Lamictal), gabapentin (Gralise, Neurontin), topiramate (Topamax), phenobarbital, and zonisamide (Zonegran)
Sources:
Advertisement
Related to this article
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
4
Can AI Help Predict Drug Shortages?
5